185 related articles for article (PubMed ID: 11319295)
41. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma.
Bogner JR; Kronawitter U; Rolinski B; Truebenbach K; Goebel FD
J Acquir Immune Defic Syndr (1988); 1994 May; 7(5):463-8. PubMed ID: 8158540
[TBL] [Abstract][Full Text] [Related]
42. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study.
Thompson DS; Hainsworth JD; Hande KR; Holzmer MC; Greco FA
J Clin Oncol; 1993 Jul; 11(7):1322-8. PubMed ID: 8315429
[TBL] [Abstract][Full Text] [Related]
43. Chemotherapy for AIDS-related and endemic African Kaposi's sarcoma in southern Africa.
Stein ME; Lachter J; Spencer D; Bezwoda WR
Int J Dermatol; 1995 Oct; 34(10):729-32. PubMed ID: 8537166
[TBL] [Abstract][Full Text] [Related]
44. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
[TBL] [Abstract][Full Text] [Related]
45. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
Yong WP; Desai AA; Innocenti F; Ramirez J; Shepard D; Kobayashi K; House L; Fleming GF; Vogelzang NJ; Schilsky RL; Ratain MJ
Cancer Chemother Pharmacol; 2007 Nov; 60(6):811-9. PubMed ID: 17308893
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents.
Kato Y; Nishimura S; Sakura N; Ueda K
Pediatr Int; 2003 Feb; 45(1):74-9. PubMed ID: 12654074
[TBL] [Abstract][Full Text] [Related]
48. Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule.
Perdaems N; Bachaud JM; Rouzaud P; Murris-Espin M; Hermant C; Mihura J; Lochon I; Houin G; Canal P; Chatelut E
Eur J Clin Pharmacol; 1998; 54(9-10):677-83. PubMed ID: 9923567
[TBL] [Abstract][Full Text] [Related]
49. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
Alici S; Saip P; Eralp Y; Aydiner A; Topuz E
Am J Clin Oncol; 2003 Aug; 26(4):358-62. PubMed ID: 12902885
[TBL] [Abstract][Full Text] [Related]
50. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
[TBL] [Abstract][Full Text] [Related]
51. Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer.
Miller AA; Tolley EA; Niell HB; Griffin JP; Mauer AM
J Clin Oncol; 1993 Jun; 11(6):1179-88. PubMed ID: 8388920
[TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer.
Millward MJ; Newell DR; Yuen K; Matthews JP; Balmanno K; Charlton CJ; Gumbrell L; Lind MJ; Chapman F; Proctor M
Cancer Chemother Pharmacol; 1995; 37(1-2):161-7. PubMed ID: 7497587
[TBL] [Abstract][Full Text] [Related]
53. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
[TBL] [Abstract][Full Text] [Related]
54. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma.
Tulpule A; Scadden DT; Espina BM; Cabriales S; Howard W; Shea K; Gill PS
J Clin Oncol; 2000 Feb; 18(4):716-23. PubMed ID: 10673512
[TBL] [Abstract][Full Text] [Related]
55. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma.
Harrison M; Tomlinson D; Stewart S
J Clin Oncol; 1995 Apr; 13(4):914-20. PubMed ID: 7707119
[TBL] [Abstract][Full Text] [Related]
56. Bioequivalence study of two formulations of etoposide in advanced lung cancer patients.
Li D; Liu L
Int J Clin Pharmacol Ther; 2015 Jun; 53(6):474-9. PubMed ID: 25828637
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe.
Borok M; Fiorillo S; Gudza I; Putnam B; Ndemera B; White IE; Gwanzura L; Schooley RT; Campbell TB
Clin Infect Dis; 2010 Aug; 51(3):342-9. PubMed ID: 20572760
[TBL] [Abstract][Full Text] [Related]
58. Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia.
Relling MV; Mahmoud HH; Pui CH; Sandlund JT; Rivera GK; Ribeiro RC; Crist WM; Evans WE
J Clin Oncol; 1996 Feb; 14(2):399-404. PubMed ID: 8636749
[TBL] [Abstract][Full Text] [Related]
59. Treatment of recurrent Kaposi's sarcoma of an AIDS patient with weekly paclitaxel.
Hsu CH; Chen MY; Cheng AL
Anticancer Res; 2000; 20(2B):1159-61. PubMed ID: 10810414
[TBL] [Abstract][Full Text] [Related]
60. Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi sarcoma. A phase II randomized, placebo-controlled trial.
Lane HC; Falloon J; Walker RE; Deyton L; Kovacs JA; Masur H; Banks S; Kirk LE; Baseler MW; Salzman NP
Ann Intern Med; 1989 Jul; 111(1):41-50. PubMed ID: 2735626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
